What Do You Need to Know About SciSparc (SPRC) Before Investing?

By Blake Campbell • Thursday, December 15 12:00 • Permanent Link

SciSparc logged a 2.2% change during today's morning session, and is now trading at a price of $0.88 per share. The S&P 500 index moved -2.5% and the Dow Industrial Average posted a -3.2% change. SPRC's trading volume is 215,916 compared to the stock's average volume of 1,139,258.

Anyone interested in buying SPRC should be aware of the facts below:

SciSparc has moved -87.8% over the last year, and the S&P 500 logged a change of -14.4%
Based on its trailing earning per share of -2.83, SciSparc has a trailing 12 month Price to Earnings (P/E) ratio of -0.3 while the S&P 500 average is 15.97
Its Price to Book (P/B) ratio is 0.3 compared to its sector average of 4.07
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.
Based in Tel Aviv, the company has 3 full time employees and a market cap of $3,096,125.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.